|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HNRNPD |
Gene summary for HNRNPD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HNRNPD | Gene ID | 3184 |
| Gene name | heterogeneous nuclear ribonucleoprotein D | |
| Gene Alias | AUF1 | |
| Cytomap | 4q21.22 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | Q14103 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3184 | HNRNPD | cSCC_p9 | Human | Skin | cSCC | 9.87e-04 | 1.25e-01 | -0.1991 |
| 3184 | HNRNPD | Pat01-B | Human | Stomach | GC | 5.17e-19 | -3.42e-01 | 0.5754 |
| 3184 | HNRNPD | Pat02-B | Human | Stomach | GC | 2.05e-59 | -4.64e-02 | 0.0368 |
| 3184 | HNRNPD | Pat03-B | Human | Stomach | GC | 4.51e-29 | -1.88e-01 | 0.3693 |
| 3184 | HNRNPD | Pat04-B | Human | Stomach | GC | 2.02e-30 | -4.66e-02 | -0.1483 |
| 3184 | HNRNPD | Pat05-B | Human | Stomach | GC | 3.93e-13 | -8.24e-02 | -0.0353 |
| 3184 | HNRNPD | Pat06-B | Human | Stomach | GC | 3.92e-60 | 1.87e-01 | -0.1961 |
| 3184 | HNRNPD | Pat09-B | Human | Stomach | GC | 5.53e-10 | -1.61e-01 | -0.0359 |
| 3184 | HNRNPD | Pat11-B | Human | Stomach | GC | 1.23e-22 | 8.85e-02 | -0.182 |
| 3184 | HNRNPD | Pat12-B | Human | Stomach | GC | 3.60e-18 | -3.05e-01 | 0.0325 |
| 3184 | HNRNPD | Pat13-B | Human | Stomach | GC | 6.20e-16 | 1.03e-01 | 0.0555 |
| 3184 | HNRNPD | Pat15-B | Human | Stomach | GC | 1.56e-19 | 3.26e-02 | -0.0778 |
| 3184 | HNRNPD | Pat16-B | Human | Stomach | GC | 2.52e-11 | -3.53e-01 | 0.1918 |
| 3184 | HNRNPD | Pat17-B | Human | Stomach | GC | 9.15e-10 | -5.36e-01 | 0.3109 |
| 3184 | HNRNPD | Pat18-B | Human | Stomach | GC | 1.06e-23 | -3.66e-02 | -0.0432 |
| 3184 | HNRNPD | Pat19-B | Human | Stomach | GC | 6.31e-15 | -9.71e-02 | 0.0826 |
| 3184 | HNRNPD | Pat22-B | Human | Stomach | GC | 8.70e-41 | 6.01e-02 | -0.1042 |
| 3184 | HNRNPD | Pat24-B | Human | Stomach | GC | 6.28e-10 | -5.27e-02 | -0.1184 |
| 3184 | HNRNPD | Pat25-A | Human | Stomach | CAG with IM | 3.40e-51 | -1.75e-01 | -0.1648 |
| 3184 | HNRNPD | Pat26-A | Human | Stomach | CSG | 1.33e-48 | -1.70e-01 | -0.2402 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
| GO:0009895 | Colorectum | AD | negative regulation of catabolic process | 124/3918 | 320/18723 | 1.66e-13 | 3.35e-11 | 124 |
| GO:0031330 | Colorectum | AD | negative regulation of cellular catabolic process | 104/3918 | 262/18723 | 2.66e-12 | 3.96e-10 | 104 |
| GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
| GO:0006401 | Colorectum | AD | RNA catabolic process | 102/3918 | 278/18723 | 8.64e-10 | 6.76e-08 | 102 |
| GO:0044270 | Colorectum | AD | cellular nitrogen compound catabolic process | 147/3918 | 451/18723 | 3.35e-09 | 2.23e-07 | 147 |
| GO:0046700 | Colorectum | AD | heterocycle catabolic process | 145/3918 | 445/18723 | 4.37e-09 | 2.84e-07 | 145 |
| GO:0006402 | Colorectum | AD | mRNA catabolic process | 87/3918 | 232/18723 | 4.40e-09 | 2.84e-07 | 87 |
| GO:0034655 | Colorectum | AD | nucleobase-containing compound catabolic process | 133/3918 | 407/18723 | 1.56e-08 | 9.12e-07 | 133 |
| GO:0019439 | Colorectum | AD | aromatic compound catabolic process | 146/3918 | 467/18723 | 7.48e-08 | 3.84e-06 | 146 |
| GO:1901361 | Colorectum | AD | organic cyclic compound catabolic process | 153/3918 | 495/18723 | 8.23e-08 | 4.18e-06 | 153 |
| GO:0061013 | Colorectum | AD | regulation of mRNA catabolic process | 64/3918 | 166/18723 | 1.44e-07 | 6.59e-06 | 64 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0051054 | Colorectum | AD | positive regulation of DNA metabolic process | 73/3918 | 201/18723 | 3.27e-07 | 1.29e-05 | 73 |
| GO:0043487 | Colorectum | AD | regulation of RNA stability | 63/3918 | 170/18723 | 9.17e-07 | 3.12e-05 | 63 |
| GO:0006417 | Colorectum | AD | regulation of translation | 141/3918 | 468/18723 | 1.32e-06 | 4.22e-05 | 141 |
| GO:0043488 | Colorectum | AD | regulation of mRNA stability | 59/3918 | 158/18723 | 1.50e-06 | 4.66e-05 | 59 |
| GO:0007623 | Colorectum | AD | circadian rhythm | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HNRNPD | SNV | Missense_Mutation | novel | c.103C>A | p.Gln35Lys | p.Q35K | Q14103 | protein_coding | tolerated_low_confidence(0.51) | benign(0) | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| HNRNPD | SNV | Missense_Mutation | c.995N>G | p.Tyr332Cys | p.Y332C | Q14103 | protein_coding | tolerated(0.05) | probably_damaging(0.926) | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| HNRNPD | SNV | Missense_Mutation | novel | c.766G>T | p.Val256Leu | p.V256L | Q14103 | protein_coding | tolerated(0.06) | benign(0.05) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HNRNPD | SNV | Missense_Mutation | novel | c.757N>A | p.Glu253Lys | p.E253K | Q14103 | protein_coding | deleterious(0.04) | possibly_damaging(0.842) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| HNRNPD | insertion | Frame_Shift_Ins | novel | c.793_794insT | p.Gln265LeufsTer8 | p.Q265Lfs*8 | Q14103 | protein_coding | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | ||
| HNRNPD | SNV | Missense_Mutation | c.1052G>A | p.Ser351Asn | p.S351N | Q14103 | protein_coding | tolerated(1) | possibly_damaging(0.878) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HNRNPD | SNV | Missense_Mutation | novel | c.565N>A | p.Leu189Ile | p.L189I | Q14103 | protein_coding | deleterious(0.01) | possibly_damaging(0.759) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HNRNPD | SNV | Missense_Mutation | c.528N>C | p.Lys176Asn | p.K176N | Q14103 | protein_coding | deleterious(0.02) | possibly_damaging(0.824) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| HNRNPD | SNV | Missense_Mutation | c.526A>C | p.Lys176Gln | p.K176Q | Q14103 | protein_coding | tolerated(0.05) | benign(0.254) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| HNRNPD | SNV | Missense_Mutation | c.464N>C | p.Met155Thr | p.M155T | Q14103 | protein_coding | deleterious(0.01) | benign(0.138) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |